Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events

Immune checkpoint inhibitors (ICIs) are able to reactivate the immune system, thereby enhancing the anti‐tumor effects. However, over‐activated T cells may induce immune‐related adverse events (irAEs). Hematological irAEs are rarely reported which mainly represent monolineage cytopenia or pancytopen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Junling, Du, Jianhua, Guo, Xiaoxiao, Zhou, Jiaxin, Duan, Lian, Qiu, Wei, Si, Xiaoyan, Zhang, Li, Li, Yue, Liu, Xiaowei, Wang, Hanping, Zhou, Daobin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Clinical Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049514/
https://www.ncbi.nlm.nih.gov/pubmed/32017466
http://dx.doi.org/10.1111/1759-7714.13281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049514/
https://www.ncbi.nlm.nih.gov/pubmed/32017466
http://dx.doi.org/10.1111/1759-7714.13281

Ejemplares similares